A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To explore whether red yeast rice is a safe and effective alternative approach for dyslipidemia. METHODS: Pubmed, the Cochrane Library, EBSCO host, Chinese VIP Information (VIP), China National Knowledge Infrastructure (CNKI), Wanfang Databases were searched for appropriate articles. Randomized trials of RYR (not including Xuezhikang and Zhibituo) and placebo as control in patients with dyslipidemia were considered. Two authors read all papers and independently extracted all relevant information. The primary outcomes were serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). The secondary outcomes were increased levels of alanine transaminase, aspartate aminotransferase, creatine kinase, creatinine and fasting blood glucose. RESULTS: A total of 13 randomized, placebo-controlled trials containing 804 participants were analyzed. Red yeast rice exhibited significant lowering effects on serum TC [WMD = -0.97 (95% CI: -1.13, -0.80) mmol/L, P<0.001], TG [WMD = -0.23 (95% CI: -0.31, -0.14) mmol/L, P<0.001], and LDL-C [WMD = -0.87 (95% CI: -1.03, -0.71) mmol/L, P<0.001] but no significant increasing effect on HDL-C [WMD = 0.08 (95% CI: -0.02, 0.19) mmol/L, P = 0.11] compared with placebo. No serious side effects were reported in all trials. CONCLUSIONS: The meta-analysis suggests that red yeast rice is an effective and relatively safe approach for dyslipidemia. However, further long-term, rigorously designed randomized controlled trials are still warranted before red yeast rice could be recommended to patients with dyslipidemia, especially as an alternative to statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A clinically relevant hypocholesterolaemic effect (up to a 20% reduction) is observed with RYR preparations providing a daily dose of ≏ 2.5-10 mg monacolin K. 146”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [146]
In the citing paper
“RYR has a mechanism of action similar to that of statins [21][22][23][24]”
In the citing paper
“Most of the other studies with RYR have been small but have consistently demonstrated its LDL-C-lowering efficacy [21].”
In the citing paper
“A clinically relevant hypocholesterolaemic effect (up to a 20% reduction) is observed with RYR preparations providing a daily dose of ~2.5e10 mg monacolin K. 146”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833 · cited 1×
“However, recently much debate has focused on the side effects of statins including myalgias and muscle weakness, reduced energy, increased fatigue, liver enzyme elevations, worsening hyperglycemia and risk of incident diabetes[6–8].”
BackgroundFarzadfar, F., Finucane, M. M., Danaei, G., Pelizzari, P. M., Cowan, M. J., Paciorek, C. J., Singh, G. M., Lin, J. K., Stevens, G. A., Riley, L. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62038-7 · Cited by 513
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
Heber, D., Yip, I., Ashley, J. M., Elashoff, D. A., Elashoff, R. M., & Go, V. L. W. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.2.231 · Cited by 499
Statins for the primary prevention of cardiovascular disease
Ebrahim, S., Taylor, F. C., & Brindle, P. (2014) · BMJ · doi:10.1136/bmj.g280 · Cited by 333
Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00006 · Cited by 275
Liu, J., Zhang, J., Shi, Y. P., Grimsgaard, S., Alræk, T., & Fønnebø, V. M. (2006) · Chinese Medicine · doi:10.1186/1749-8546-1-4 · Cited by 240
Mancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., & Pope, J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 188 · cited 1×
“However, recently much debate has focused on the side effects of statins including myalgias and muscle weakness, reduced energy, increased fatigue, liver enzyme elevations, worsening hyperglycemia and risk of incident diabetes[6–8].”
BackgroundMarked Variability of Monacolin Levels in Commercial Red Yeast Rice Products: Buyer Beware!
Gordon, R. Y., Cooperman, T., Obermeyer, W., & Becker, D. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.382 · Cited by 184 · cited 1×
“In the US, the FDA recognizes these supplements as drugs when they contain a standardized, specific amount of lovastatin[38].”
BackgroundSathasivam, S. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.01.004 · Cited by 165 · cited 1×
“glucose; the results showed that RYR has no significant increasing effect on serum CK level compared with placebo, which is preferable to statins because of the increasing statin-associated myalgias and CK increasing side effects[29–31].”
BackgroundHalbert, S. C., French, B., Gordon, R. Y., Farrar, J. T., Schmitz, K., Morris, P. B., Thompson, P. D., Rader, D. J., & Becker, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.672 · Cited by 154
Affuso, F., Ruvolo, A., Micillo, F., Saccà, L., & Fazio, S. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.05.017 · Cited by 149
Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., & Rosano, G. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0082-5 · Cited by 107
Review of red yeast rice content and current Food and Drug Administration oversight
Childress, L., Gay, A., Zargar, A., & Ito, M. K. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.09.003 · Cited by 92 · cited 1×
“In addition to lovastatin, most RYR preparations contain other active substances such as Coenzyme Q10 and isoflavones[10,36].”
BackgroundLipid-Lowering Efficacy of Red Yeast Rice in a Population Intolerant to Statins
Venero, C. V., Venero, J., Wortham, D. C., & Thompson, P. D. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.045 · Cited by 92 · cited 1×
“Clinical studies suggest that RYR has the potential to reduce serum LDL-C levels by 10% to 33%[11–13].”
BackgroundSimvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial
Becker, D. J., Gordon, R. Y., Morris, P. B., Yorko, J., Gordon, Y. J., Li, M., & Iqbal, N. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.758 · Cited by 91
Guardamagna, O., Abello, F., Baracco, V., Stasiowska, B., & Martino, F. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.10.015 · Cited by 84
Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products
Chen, C.-H., Yang, J., Uang, Y., & Lin, C. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.028 · Cited by 80 · cited 1×
“This indicates that probably the activity of RYR is much higher than predicted based on the very low doses generally given to patients[37].”
BackgroundThe effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders
Yang, C., & Mousa, S. A. (2012) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2012.07.004 · Cited by 80 · cited 2×
“The constituents of RYR include Monacolin K (lovastatin) and other active ingredients that are thought to play a role in the management of hyperlipidemia[10].”
BackgroundHypoCol (red yeast rice) lowers plasma cholesterol – a randomized placebo controlled study
Bogsrud, M. P., Ose, L., Langslet, G., Ottestad, I., Strøm, E. C., Hagve, T.-A., & Retterstøl, K. (2010) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431003624123 · Cited by 73 · cited 1×
“Trials Description A total of 13 randomized controlled trials[16–28] from 1999 to 2013 containing 804 participants were included, and all trials were published in English.”
BackgroundEfficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients
Huang, C.-F., Li, T.-C., Lin, C.-C., Liu, C.-S., Shih, H.-C., & Lai, M.-M. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32801da137 · Cited by 65 · cited 2×
“TC, TG, LDL-C, HDL-C were reported in most of trials except Huang 2007[27], in which only TC and LDL-C were reported and Karl 2012[20] in which only TC, LDL-C and HDLC were reported.”
BackgroundResultStatins, Cardiovascular Disease, and Drug Safety
Gotto, A. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.005 · Cited by 54 · cited 1×
“However, recently much debate has focused on the side effects of statins including myalgias and muscle weakness, reduced energy, increased fatigue, liver enzyme elevations, worsening hyperglycemia and risk of incident diabetes[6–8].”
BackgroundStatin-Induced Myopathy: The Two Faces of Janus
Arora, R. R., Liebo, M., & Maldonado, F. A. (2006) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248406288758 · Cited by 54 · cited 1×
“glucose; the results showed that RYR has no significant increasing effect on serum CK level compared with placebo, which is preferable to statins because of the increasing statin-associated myalgias and CK increasing side effects[29–31].”
BackgroundAbello, F., Baracco, V., Stasiowska, B., Martino, F., & Guardamagna, O. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/s0939-4753(09)70002-x · Cited by 50
Ogier, N., Amiot, M.-J., Georgé, S., Maillot, M., Mallmann, C., Maraninchi, M., Morange, S., Lescuyer, J.-F., Peltier, S. L., & Cardinault, N. (2013) · European Journal of Nutrition · doi:10.1007/s00394-012-0357-x · Cited by 49
Cicero, A. F. G., Brancaleoni, M., Laghi, L., Donati, F., & Mino, M. (2005) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2005.07.008 · Cited by 43 · cited 1×
“There were other studies also showing that RYR was tolerated as well as simvastatin or pravastatin and achieved a comparable reduction of LDL-C, without clinically relevant changes in liver and muscular toxicity markers[32–34].”
ResultLee, I., Lee, W., Tsai, C.-M., Su, I., Yen, H.-T., & Sheu, W. H. (2012) · Nutrition Research · doi:10.1016/j.nutres.2011.12.011 · Cited by 41 · cited 5×
“Trials Description A total of 13 randomized controlled trials[16–28] from 1999 to 2013 containing 804 participants were included, and all trials were published in English.”
BackgroundMethodResultInfluentialEfficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia
Gheith, O. A. A., Sheashaa, H., Abdelsalam, M. A. M., Shoeir, Z., & Sobh, M. A. K. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0033-x · Cited by 35 · cited 1×
“Moreover, RYR was proved effective, safe and well tolerated in nephrotic dyslipidemia both in adults and children and in familial hypercholesterolemia children[39,40].”
BackgroundBarrat, E., Zaïr, Y., Ogier, N., Housez, B., Vergara, C., Maudet, C., Lescuyer, J.-F., Bard, J.-M., Carpentier, Y. A., Cazaubiel, M., et al. (2013) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2013.809405 · Cited by 34
Barrat, E., Zaïr, Y., Sirvent, P., Chauveau, P., Maudet, C., Housez, B., Derbord, E., Lescuyer, J.-F., Bard, J.-M., Cazaubiel, M., et al. (2013) · European Journal of Nutrition · doi:10.1007/s00394-012-0486-2 · Cited by 31
Higashikawa, F., Noda, M., Awaya, T., Ushijima, M., & Sugiyama, M. (2011) · Clinical Nutrition · doi:10.1016/j.clnu.2011.10.008 · Cited by 26 · cited 1×
“Five [17,18,20,21,26] of the studies reported the methods of random sequence generation.”
BackgroundYang, N.-C., Chou, C., Chen, C.-Y., Hwang, K.-L., & Yang, Y.-C. (2009) · PubMed · Cited by 26
Karl, M., Rubenstein, M., Rudnick, C., & Brejda, J. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.09.004 · Cited by 21 · cited 6×
“Most of the studies reported serum TG levels at baseline and after intervention except 2 trials[20,27].”
BackgroundMethodResultInfluentialRoss, S. M. (2012) · Holistic Nursing Practice · doi:10.1097/hnp.0b013e3182510596 · Cited by 9
Should anyone still be taking simvastatin 80 mg?
Tayal, U., & Carroll, R. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-200415 · Cited by 6
Research works printed but not linked: 2
- Erdogrul O, Azirak S (2005) A review on the red yeast rice (Monascus purpureus). KSU Journal of Science and Engineering 8: 10– 15.
- Lu JH, Bonovich K, Colfer H, Davidson M, Dujovne CA, et al (2013) Clinical study on cholesterol-lowering effect of RYR Cholestin among Americans with moderate hy-percholesterolemia. Shanghai Journal of Preventive Medicine 25: 501– 506.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“[once daily (omni die)] dose of 5 10 mg monacolin K.(145) Nutraceuticals containing purified RYR may be considered in people with elevated 26 ESC/EAS Guidelines”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“5–10 mg monacolin K.(146) Nutraceuticals containing purified RYR may be considered in people with elevated plasma cholesterol concentrations who do not qualify for treatment with statins in view of their global CV risk.”
BackgroundStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Metadata
- Authors
- Li, Y., Jiang, L., Jia, Z., Xin, W., Yang, S., Yang, Q., & Wang, L.
- Affiliations
- Capital Medical University (CN)
- Corresponding author
- Wang, Luya
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-04
- Volume
- 9
- Issue
- 6
- Pages
- e98611
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4045580
- OpenAlex
- W2067614264
- Cited by
- 124
- References
- 40
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 13 · 2020: 14 · 2019: 11 · 2018: 15 · 2017: 11 · 2016: 20 · 2015: 12
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (81170810)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- red yeast rice, dyslipidemia, hypercholesterolemia, total cholesterol, LDL cholesterol, triglycerides, HDL cholesterol, statin alternatives, hepatotoxicity, drug safety, hypolipidemic effect
- MeSH terms
- Complementary Therapies, Biological Products, Humans, Lipids, Liver Function Tests, Randomized Controlled Trials as Topic, Treatment Outcome, Publication Bias, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.